Jan A Walewski

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9215005/publications.pdf

Version: 2024-02-01

124	10,703	117453	31759
papers	citations	34	101
		h-index	g-index

127	127	127	8741
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology, The, 2006, 7, 379-391.	5.1	1,840
2	CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 2005, 105, 1417-1423.	0.6	896
3	CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncology, The, 2011, 12, 1013-1022.	5.1	633
4	Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2015, 385, 1853-1862.	6.3	633
5	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkinâ€™s Lymphoma. New England Journal of Medicine, 2018, 378, 331-344.	13.9	564
6	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet, The, 2017, 390, 555-566.	6.3	444
7	Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease. New England Journal of Medicine, 2007, 357, 1916-1927.	13.9	412
8	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. Journal of Clinical Oncology, 2015, 33, 2492-2499.	0.8	394
9	Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood, 2008, 111, 1094-1100.	0.6	369
10	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet, The, 2016, 388, 565-575.	6.3	328
11	Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 424-435.	5.1	304
12	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood, 2008, 111, 5486-5495.	0.6	247
13	Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood, 2010, 115, 3215-3223.	0.6	243
14	Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood, 2014, 124, 3870-3879.	0.6	236
15	A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood, 2008, 112, 2248-2260.	0.6	199
16	Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood, 2002, 99, 4379-4385.	0.6	195
17	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Annals of Oncology, 2013, 24, 561-576.	0.6	193
18	Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncology, The, 2008, 9, 435-444.	5.1	190

#	Article	IF	Citations
19	Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood, 2018, 132, 2639-2642.	0.6	172
20	Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network. Journal of Clinical Oncology, 2014, 32, 1338-1346.	0.8	137
21	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002;) Tj ETQq1 1 0.784314 rgBT /Over	5.1	135
22	Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Journal of Clinical Oncology, 2005, 23, 9208-9218.	0.8	130
23	Rituximab Purging and/or Maintenance in Patients Undergoing Autologous Transplantation for Relapsed Follicular Lymphoma: A Prospective Randomized Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2013, 31, 1624-1630.	0.8	111
24	Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncology, The, 2011, 12, 773-784.	5.1	98
25	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood, 2020, 135, 735-742.	0.6	86
26	Central nervous system involvement by multiple myeloma: A multiâ€institutional retrospective study of 172 patients in daily clinical practice. American Journal of Hematology, 2016, 91, 575-580.	2.0	83
27	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematology,the, 2021, 8, e410-e421.	2.2	83
28	Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. New England Journal of Medicine, 2022, 386, 2482-2494.	13.9	83
29	Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. Journal of Clinical Oncology, 2020, 38, 248-256.	0.8	73
30	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Annals of Oncology, 2018, 29, 544-562.	0.6	64
31	Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement. Medical Oncology, 2011, 28, 1589-1595.	1.2	46
32	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physicianâ€™s choice in cutaneous T-cell lymphoma: final data. Blood Advances, 2021, 5, 5098-5106.	2.5	46
33	Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood, 2014, 123, 3255-3262.	0.6	45
34	A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration. Modern Pathology, 2018, 31, 732-743.	2.9	42
35	Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1â€“2 study. British Journal of Haematology, 2010, 150, 58-71.	1.2	37
36	Immunogenicity of Influenza Vaccination in Patients with Non-Hodgkin Lymphoma. Journal of Clinical Immunology, 2007, 27, 339-346.	2.0	34

#	Article	IF	Citations
37	Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-HodgkinÊ¼s Lymphoma. Clinical Pharmacokinetics, 2011, 50, 781-791.	1.6	31
38	Primary Mediastinal Large B-cell Lymphoma. Current Hematologic Malignancy Reports, 2014, 9, 273-283.	1.2	31
39	Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. British Journal of Haematology, 2016, 175, 860-867.	1.2	30
40	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leukemia and Lymphoma, 2016, 57, 2071-2076.	0.6	30
41	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. Leukemia and Lymphoma, 2011, 52, 2226-2236.	0.6	29
42	Response to brentuximab vedotin versus physicianâ€™s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. European Journal of Cancer, 2021, 148, 411-421.	1.3	27
43	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL) Tj ETQq1 1 0.784314 rgBT /Ove	0.6	27
44	Individual Quality Assessment of Autografting by Probability Estimation for Clinical Endpoints: A Prospective Validation Study from the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1670-1676.	2.0	26
45	The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica, 2016, 101, 235-240.	1.7	24
46	Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. Leukemia and Lymphoma, 2018, 59, 1814-1828.	0.6	23
47	Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning. European Journal of Cancer, 2018, 104, 127-136.	1.3	23
48	Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated lowâ€grade Bâ€cell nonâ€Hodgkin lymphoma patients. Cancer, 2008, 113, 367-375.	2.0	22
49	PD-L1 Overexpression, SWI/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4+ T Cells. Cancers, 2021, 13, 4148.	1.7	22
50	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. European Journal of Cancer, 2020, 133, 120-130.	1.3	21
51	Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse. Blood, 2015, 126, 3172-3172.	0.6	20
52	Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients. Medical Oncology, 2012, 29, 2966-2977.	1.2	18
53	Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multiâ€agent chemotherapy. British Journal of Haematology, 2018, 183, 400-410.	1.2	18
54	miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large Bâ€“cell lymphoma. Tumor Biology, 2015, 36, 5377-5388.	0.8	17

#	Article	IF	Citations
55	Current Treatment of Chronic Lymphocytic Leukemia. Current Treatment Options in Oncology, 2017, 18, 5.	1.3	17
56	Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study. Leukemia and Lymphoma, 2019, 60, 675-684.	0.6	17
57	Frequent aberrations of chromosome 8 in aggressive B-cell non-Hodgkin lymphoma. Cancer Genetics and Cytogenetics, 2005, 156, 114-121.	1.0	16
58	Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naÃ¯ve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. Journal of Hematology and Oncology, 2012, 5, 67.	6.9	16
59	Firstâ€line Râ€CVP versus Râ€CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. British Journal of Haematology, 2020, 188, 898-906.	1.2	16
60	FcÎ³RIIA and FcÎ³RIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2011, 52, 1604-1606.	0.6	15
61	Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigatorâ€™s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study. Blood, 2014, 124, 626-626.	0.6	15
62	Serum macrophage colony-stimulating factor (M-CSF) in patients with Hodgkin lymphoma. Medical Oncology, 2012, 29, 2143-2147.	1.2	14
63	Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas. Cancers, 2019, 11, 1647.	1.7	14
64	Human regulatory T cells suppress proliferation of B lymphoma cells. Leukemia and Lymphoma, 2016, 57, 1903-1920.	0.6	13
65	Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. Leukemia and Lymphoma, 2020, 61, 2931-2938.	0.6	13
66	Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective. BMC Cancer, 2020, 20, 1088.	1.1	12
67	Fine Needle Aspiration Biopsy with Flow Cytometry Is a Reliable Method for Defining Immunophenotype of Prognostic Value in T Lymphoblastic Lymphoma.. Blood, 2009, 114, 3928-3928.	0.6	11
68	Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) Guidelines on the Use of Granulocyte Colony-Stimulating Factor (G-CSF) for Lymphoma Care. Clinical Drug Investigation, 2009, 29, 491-513.	1.1	10
69	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2016. Acta Haematologica Polonica, 2016, 47, 39-85.	0.1	10
70	Lenalidomide potentiates CD4+CD25+Treg-related suppression of lymphoma B-cell proliferation. Clinical and Experimental Medicine, 2017, 17, 193-207.	1.9	10
71	The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2017, 58, 594-600.	0.6	10
72	Prospective subgroup analyses of the randomized <scp>MCL</scp>â€002 (<scp>SPRINT</scp>) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. British Journal of Haematology, 2018, 180, 224-235.	1.2	10

#	Article	IF	Citations
73	Addition of High-Dose Cytarabine to Immunochemotherapy before Autologous Stem-Cell Transplantation in Patients Aged 65 Years or Younger with Mantle Cell Lymphoma (MCL Younger): A Long-Term Follow-up of the Randomized, Open-Label, Phase 3 Trial of the European Mantle Cell Lymphoma Network. Blood, 2021, 138, 380-380.	0.6	10
74	Recovery of dendritic cell counts and function in peripheral blood of cancer patients after chemotherapy. Cytokines, Cellular & Molecular Therapy, 2002, 7, 15-24.	0.3	9
75	Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma. Clinical Biochemistry, 2010, 43, 604-608.	0.8	9
76	Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis. Annals of Hematology, 2013, 92, 925-933.	0.8	9
77	Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma. American Journal of Therapeutics, 2016, 23, e749-e756.	0.5	9
78	Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2017, 58, 2356-2362.	0.6	9
79	Unusual Cyclin D1 Positive Marginal Zone Lymphoma of Mediastinum. Medical Oncology, 2006, 23, 423-428.	1.2	8
80	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205). Blood, 2020, 136, 22-23.	0.6	8
81	A survey of prognostic value of serum factors in multiple myeloma patients before treatment: macrophage-colony stimulating factor (M-CSF) is a powerful predictor of survival. Medical Oncology, 2011, 28, 194-198.	1.2	7
82	Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma. Tumor Biology, 2012, 33, 1733-1738.	0.8	7
83	Population-based epidemiological data of follicular lymphoma in Poland: 15Âyears of observation. Scientific Reports, 2020, 10, 14610.	1.6	7
84	Higher genome variability within metabolism genes associates with recurrent Clostridium difficile infection. BMC Microbiology, 2021, 21, 36.	1.3	7
85	Mantle Cell Lymphoma Presenting with Paraproteinemia. Medical Oncology, 2005, 22, 319-324.	1.2	6
86	Primary refractory multiple myeloma: a real-world experience with 85 cases. Leukemia and Lymphoma, 2020, 61, 2868-2875.	0.6	6
87	Unusual IgD+/CD38-Follicular Lymphoma with Leukemic Presentation. Medical Oncology, 2006, 23, 131-136.	1.2	5
88	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytowego na rok 2012. Acta Haematologica Polonica, 2012, 43, 7-47.	0.1	5
89	Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant. Leukemia and Lymphoma, 2013, 54, 973-978.	0.6	5
90	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2017. Acta Haematologica Polonica, 2017, 48, 55-103.	0.1	5

#	Article	IF	Citations
91	Aggressive B-Cell Lymphoma: Chasing the Target. Journal of Investigative Medicine, 2020, 68, 331-334.	0.7	5
92	Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. Blood, 2020, 136, 26-28.	0.6	5
93	European MCL Network: An Update on Current First Line Trials.. Blood, 2007, 110, 388-388.	0.6	5
94	Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group. Polish Archives of Internal Medicine, 2015, 125, 741-748.	0.3	5
95	CHOP-21 for unfavorable Hodgkinâ€™s lymphoma. An exploratory study. Medical Oncology, 2010, 27, 262-267.	1.2	4
96	Bendamustine as Monotherapy and in Combination Regimens for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma: A Retrospective Analysis. Chemotherapy, 2013, 59, 280-289.	0.8	4
97	Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation. Leukemia and Lymphoma, 2021, 62, 3031-3034.	0.6	4
98	Comparision of benefits of early, delayed, and no administration of G-CSF after autologous peripheral blood stem cell transplantation in lymphoma patients. Annals of Transplantation, 2013, 18, 336-341.	0.5	4
99	The Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 As Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-Cell Malignancies. Blood, 2021, 138, 1549-1549.	0.6	4
100	Significance of CD10 protein expression in the diagnostics of follicular lymphoma: A comparison of conventional immunohistochemistry with flow cytometry supported by the establishment of BCL2 and BCL6 rearrangements. International Journal of Laboratory Hematology, 2020, 42, 453-463.	0.7	3
101	Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis. Leukemia and Lymphoma, 2013, 54, 790-793.	0.6	2
102	PD1 distribution pattern, regardless of the cell origin, is an independent microenvironmental prognostic factor for progression-free survival in follicular lymphoma. Pathology Research and Practice, 2020, 216, 153096.	1.0	2
103	Prognostic Value of the Immunological Subtypes of Adolescent and Adult T-Cell Lymphoblastic Lymphoma; an Ultra-High-Risk Pro-T/CD2(â^) Subtype. Cancers, 2021, 13, 1911.	1.7	2
104	DA-EPOCH-R Is an Effective Regimenin High Grade B-Cell Lymphoma Defined By Cell-of-Origin, Karyotype and BCL2/MYC/BCL6 Status and Expression. Blood, 2016, 128, 1754-1754.	0.6	2
105	Improved survival of Burkitt lymphoma/leukemia patients: observations from Poland, 1999â€“2020. Annals of Hematology, 2022, 101, 1059-1065.	0.8	2
106	High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up. Scientific Reports, 2022, 12, .	1.6	2
107	Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy. Medical Oncology, 1996, 13, 199-205.	1.2	1
108	EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment. Anticancer Research, 2020, 40, 6685-6697.	0.5	1

#	Article	IF	Citations
109	Isolation and Characteristics of Dendritic Cell Progenitors from the Bone Marrow of the Hodgkinâ€™s Disease Patients. Advances in Experimental Medicine and Biology, 1995, 378, 553-555.	0.8	1
110	CHOP Chemotherapy for Unfavorable or Advanced Hodgkinâ€™s Lymphoma. A Pilot Study.. Blood, 2004, 104, 1311-1311.	0.6	1
111	Flow Cytometry and Cytogenetics of Fine Needle Aspiration Biopsy Samples Is a Reliable Method for Diagnosing Burkitt Lymphoma. Evaluation of 78 Cases from a Single-Institution. Blood, 2014, 124, 1640-1640.	0.6	1
112	Significance of a Critical Set of 11q Chromosome Aberrations for Diagnosis of MYC Negative Burkitt Lymphoma. Blood, 2015, 126, 2679-2679.	0.6	1
113	Serendipity w drodze do skutecznego leczenia: poczÄ…tki i perspektywy immunochemioterapii, czyli od nitrogranulogenu do receptorÃ³w chimerowych. Nowotwory, 2015, 65, 96-102.	0.1	1
114	Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantationâ€ineligible relapsed and refractory diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2022, , .	1.2	1
115	Monoclonal antibody therapy for classical Hodgkin lymphoma. Clinical Investigation, 2013, 3, 899-910.	0.0	0
116	Follow-up in aggressive lymphomas. Memo - Magazine of European Medical Oncology, 2014, 7, 80-82.	0.3	0
117	ChÅ‚oniaki agresywne z komÃ³rek B z podwÃ³jnÄ…/potrÃ³jnÄ… translokacjÄ… â€“ double/triple hit lymphoma. Acta Haematologica Polonica, 2015, 46, 263-268.	0.1	0
118	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ…ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2015. Acta Haematologica Polonica, 2015, 46, 159-211.	0.1	0
119	MoÅ¼liwoÅ›ci leczenia indukcyjnego chorych na szpiczaka plazmocytowego kwalifikujÄ…cych siÄ™ do chemioterapii wysokodawkowanej wspomaganej autologicznÄ… transplantacjÄ… komÃ³rek krwiotwÃ³rczych a aktualne zalecenia Polskiej Grupy Szpiczakowej. Acta Haematologica Polonica, 2017, 48, 104-111.	0.1	0
120	Peripheral Blood Cells from Patients with Hodgkinâ€™s and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs. BioMed Research International, 2021, 2021, 1-9.	0.9	0
121	Czy naleÅ¼y stosowaÄ‡ radioterapiÄ™ w chÅ‚oniaku rozlanym z duÅ¼ych komÃ³rek B? GÅ‚os na nie. Nowotwory, 2014, 64, 81-83.	0.1	0
122	Czynniki pobudzajÄ…ce granulopoezÄ™ sÄ… naduÅ¼ywane w systemowym leczeniu onkologicznym. Nowotwory, 2016, 65, 529-534.	0.1	0
123	Stanowisko polskich ekspertÃ³w dotyczÄ…ce zastosowania leku brentuksymab vedotin w leczeniu chorych na pierwotne chÅ‚oniaki skÃ³ry CD30+. Hematologia, 2018, 9, 83-89.	0.0	0
124	Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma - Real World Report of Polish Lymphoma Research Group. Chemotherapy, 2022, , .	0.8	0